SCHEMBL23826809

SCHEMBL23826809

C[C@H](N)C1(C)CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TSHR P16473 2/20 0.43
ALOX15 P16050 1/20 0.43
HPGD P15428 1/20 0.41
EPHX2 P34913 1/20 0.40
ATM Q13315 2/20 0.40
HTT P42858 2/20 0.40
ALDH1A1 P00352 2/20 0.39
MAPT P10636 2/20 0.39
NPC1 O15118 1/20 0.39
MAPK1 P28482 1/20 0.39
RAB9A P51151 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
RECQL P46063 1/20 0.39
EPHX1 P07099 1/20 0.39
DPP4 P27487 1/20 0.39
LMNA P02545 1/20 0.39
GRIN2B Q13224 1/20 0.38
GRIN2C Q14957 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22196335 1.00 USP2 (0.47) USP2SMN1; SMN2TSHRALOX15HPGD
SCHEMBL12349928 0.87 USP2 (0.50) USP2SMN1; SMN2TSHRALOX15HPGD
SCHEMBL28867494 0.85 USP2 (0.49) USP2SMN1; SMN2TSHRALOX15HPGD
SCHEMBL18423086 0.84 USP2 (0.47) USP2SMN1; SMN2TSHRALOX15HPGD
SCHEMBL25847257 0.84 USP2 (0.47) USP2SMN1; SMN2TSHRALOX15HPGD
SCHEMBL15657911 0.84 USP2 (0.47) USP2SMN1; SMN2TSHRALOX15HPGD
SCHEMBL25847258 0.84 USP2 (0.47) USP2SMN1; SMN2TSHRALOX15HPGD
SCHEMBL20964373 0.83 USP2 (0.44) USP2SMN1; SMN2TSHRALOX15HPGD
SCHEMBL23826577 0.83 USP2 (0.46) USP2SMN1; SMN2TSHRALOX15HPGD
SCHEMBL23826580 0.83 USP2 (0.46) USP2SMN1; SMN2TSHRALOX15HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113302184-B 1,3, 4-Oxadiazolinone compounds and medicaments 日本新药株式会社 2024-11-22 CN disclosed
US-20220024921-A1 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL NIPPON SHINYAKU CO., LTD. (JP) 2022-01-27 US disclosed
EP-3882239-A1 1,3,4-OXADIAZOLONE COMPOUND AND MEDICINE Nippon Shinyaku Co., Ltd. (JP) 2021-09-22 EP disclosed
CN-113302184-A 1,3, 4-oxadiazolinone compounds and drugs 日本新药株式会社 2021-08-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220024921-A1 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL PIM1, PIM3, PIM2 USP2 4793/4885SMN1; SMN2 4744/4885TSHR 4341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.